Proglo Pharmaceutical: Announcement on the progress of guarantees for subsidiary companies
Prologis Pharmaceuticals: Investor Relations Activity Record Form for October 18, 2024
Prologis Pharmaceuticals: Announcement on amantadine hydrochloride tablets being approved for marketing by the US FDA
Proglo Pharmaceutical: Announcement on the progress of guarantees for subsidiary companies
Proglo Pharmaceutical: Announcement on the progress of guarantees for subsidiary companies
Apeloa Pharmaceutical: Investor relations activity record form for August 16, 2024.
Apeloa Pharmaceutical: Announcement on Progress Made Regarding Guarantees for Subsidiary Companies.
Apeloa Pharmaceutical: Announcement on Progress Made Regarding Guarantees for Subsidiary Companies.
Apeloa Pharmaceutical: Announcement on the progress of guarantees for subsidiary companies
Prologis Pharmaceuticals: Investor Relations Activity Record Form for April 18, 2024
Propulo Pharmaceutical: Announcement of Resolutions of the 6th Meeting of the 9th Board of Directors
Proglo Pharmaceutical: Announcement on the progress of guarantees for subsidiary companies
Propulo Pharmaceutical: Announcement of Resolutions of the Fifth Meeting of the 9th Board of Directors
Prologis Pharmaceuticals: Investor Relations Activity Record Form for March 21, 2024
Prologis Pharmaceuticals: Announcement on holding an online performance briefing for the 2023 Annual Report
Pro-Pharmaceutical:000739 Pro-PharmaceuticalInvestor Relations Management Information 20240308
Prologis Pharmaceuticals: Independent Director's Debriefing Report (Chen Ling)
Prologis Pharmaceuticals: Review Opinions of the 9th Board of Directors at the First Special Meeting of Independent Directors
Prologis Pharmaceutical: Independent Director's Debriefing Report (Qian Juanping)
Prologis Pharmaceutical: Annual Special Audit Report on Related Party Capital Occupation
No Data
No Data